With Trio Of 2011 Deals, Alexion Looks To Nearly Double R&D Spending In 2012
This article was originally published in The Pink Sheet Daily
The biotech, which is enjoying growing sales of high-priced, ultra-orphan terminal complement inhibitor Soliris, also has a pipeline of four other clinical and preclinical candidates for rare diseases.
You may also be interested in...
Alnylam’s release of early-stage clinical data for its lead amyloidosis project in July caused a surge in its market value and rare cheers from investors. Years removed from its most recent high-profile technology deal, Alnylam is a company on the verge of completing the trickiest metamorphosis in biotech: from technology platform to product focus without the benefit of transformational M&A.
Alexion could pay as much as $1.08 billion for access to Enobia's mid-stage rare disease compound asfotase alpha.
The devastating natural course of atypical hemolytic uremic syndrome, coupled with the small quantity of drug used to treat pediatric patients, means the new use is expected to have only a small impact on sales initially, Alexion's management says.